GLP-2 TZ
GLP-2 TZ is a lyophilized research peptide in the Rogue Compounds GLP Collection, offered in 10mg, 20mg and 30mg vials. It belongs to the class of dual GIP/GLP-1 receptor agonists: single peptides designed to activate both incretin receptors. The name is a catalog code; the product is not glucagon-like peptide-2 and does not target the GLP-2 receptor.
Product Specifications
- Product: GLP-2 TZ
- Amount: 10mg / 20mg / 30mg
- Form: Lyophilized powder
- Purity: Third-party tested by an ISO 17025 U.S. laboratory. The batch Certificate of Analysis (COA) is posted on this page when the batch is in stock.
- Storage: Keep sealed and refrigerated at 2–8°C (36–46°F), protected from light.
- Ships from: United States, 2-day UPS
Compound identifiers are provided on the batch Certificate of Analysis.
The receptor biology
The two incretin hormones, GLP-1 and GIP, are released from the gut after nutrient intake. Their receptors are closely related class B G protein-coupled receptors that both signal mainly through Gs and cAMP:
- GIP receptor: activated by glucose-dependent insulinotropic polypeptide from intestinal K-cells. It is expressed on pancreatic islet cells, in adipose tissue and in parts of the brain. Whether GIP-receptor activation or blockade is the more useful experimental strategy remains debated, and both approaches are studied.
- GLP-1 receptor: activated by glucagon-like peptide-1 from intestinal L-cells, and expressed in pancreatic β-cells, the brainstem and hypothalamus, heart and gut.
The native ligands share sequence features at the N-terminus, which is what made it possible to design single peptides that bind both receptors.
What researchers study
Dual agonists let laboratories examine what combined incretin-receptor signaling does compared with activating either receptor alone. Typical questions include:
- Receptor balance: relative potency at each receptor, since a dual agonist is rarely equipotent at both.
- Signaling bias: cAMP generation versus β-arrestin recruitment, and how that affects receptor internalization and desensitization.
- Species differences: GIP-receptor pharmacology differs between human and rodent receptors, which matters when translating cell data to animal models.
- Preclinical comparisons: single, dual and triple incretin-receptor agonists studied side by side.
Regulatory status
GLP-2 TZ is not an FDA-approved drug and is not sold for human or veterinary use. It is a research reagent only.
Quality & Documentation
Every batch of GLP-2 TZ is made in small runs for Rogue Compounds and tested by an independent U.S. laboratory for identity (mass spectrometry) and purity (HPLC). Each vial is labeled with its batch number and a QR code that opens the testing lab’s own report for that batch. When a batch is in stock, its Certificate of Analysis is posted on this page and in our COA Library, so you can check one against the other.
Background reading on the receptors
- Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819-837. PMID 23684623
- Campbell JE, Drucker DJ. Therapeutic targeting of the GIP receptor: revisiting the controversies. Diabetes. 2025;74(8):1320-1325. PMID 40521880
- Müller TD, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. PMID 31767182
- Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27:740-756. PMID 29617641
Research Use Only
This product is sold strictly as a research chemical for in-vitro laboratory and analytical use by qualified professionals. It is not a drug, dietary supplement, food, or cosmetic, and it is not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Rogue Compounds does not provide dosing, preparation, or usage instructions. The literature on this page is listed for scientific background only and does not describe this product or any use of it.
